NRG2

Summary

NRG2 (neuregulin 2, HGNC:7998) is a protein-coding gene on chromosome 5q31.2, encoding Pro-neuregulin-2, membrane-bound isoform (O14511). Direct ligand for ERBB3 and ERBB4 tyrosine kinase receptors.

This gene encodes a novel member of the neuregulin family of growth and differentiation factors. Through interaction with the ERBB family of receptors, this protein induces the growth and differentiation of epithelial, neuronal, glial, and other types of cells. The gene consists of 12 exons and the genomic structure is similar to that of neuregulin 1, another member of the neuregulin family of ligands. The products of these genes mediate distinct biological processes by acting at different sites in tissues and eliciting different biological responses in cells. This gene is located close to the region for demyelinating Charcot-Marie-Tooth disease locus, but is not responsible for this disease. Alternative transcript variants encoding distinct isoforms have been described.

Source: NCBI Gene 9542 — RefSeq curated summary.

At a glance

• Gene–disease (curated): intellectual disability (Limited, GenCC)
• GWAS associations: 4
• Clinical variants (ClinVar): 134 total
• MANE Select transcript: NM_004883

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7998
Approved symbol	NRG2
Name	neuregulin 2
Location	5q31.2
Locus type	gene with protein product
Status	Approved
Aliases	Don-1, NTAK, HRG2
Ensembl gene	ENSG00000158458
Ensembl biotype	protein_coding
OMIM	603818
Entrez	9542

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 7 protein_coding, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000289409, ENST00000289422, ENST00000340391, ENST00000358522, ENST00000361474, ENST00000378238, ENST00000518130, ENST00000519478, ENST00000541337, ENST00000956720

RefSeq mRNA: 6 — MANE Select: NM_004883 NM_001184935, NM_001410780, NM_004883, NM_013981, NM_013982, NM_013983

CCDS: CCDS4217, CCDS54910, CCDS93793

Canonical transcript exons

ENST00000361474 — 10 exons

Exon	Start	End
ENSE00001039022	139865549	139865625
ENSE00002296594	140042370	140043299
ENSE00003491263	139846781	139848697
ENSE00003543174	139852904	139853027
ENSE00003568489	139851604	139851831
ENSE00003585293	139887340	139887511
ENSE00003589254	139880856	139880974
ENSE00003597009	139871721	139871841
ENSE00003613079	139852432	139852559
ENSE00003640351	139855676	139855778

Expression profiles

Bgee: expression breadth ubiquitous, 204 present calls, max score 96.76.

FANTOM5 (CAGE): breadth broad, TPM avg 1.0835 / max 60.6370, expressed in 416 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
63779	0.8892	367
63777	0.1942	106

Top tissues by expression

268 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	96.76	gold quality
paraflocculus	UBERON:0005351	92.28	gold quality
frontal pole	UBERON:0002795	91.08	gold quality
middle frontal gyrus	UBERON:0002702	89.94	gold quality
Brodmann (1909) area 10	UBERON:0013541	84.46	gold quality
cerebellar vermis	UBERON:0004720	82.80	gold quality
right hemisphere of cerebellum	UBERON:0014890	82.27	gold quality
cerebellar cortex	UBERON:0002129	82.16	gold quality
cerebellar hemisphere	UBERON:0002245	82.14	gold quality
cerebellum	UBERON:0002037	81.96	gold quality
endometrium epithelium	UBERON:0004811	81.31	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.54	silver quality
gastrocnemius	UBERON:0001388	78.31	gold quality
left ovary	UBERON:0002119	77.94	gold quality
right ovary	UBERON:0002118	77.49	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	76.53	gold quality
muscle of leg	UBERON:0001383	76.20	gold quality
minor salivary gland	UBERON:0001830	74.89	gold quality
endocervix	UBERON:0000458	74.82	gold quality
ovary	UBERON:0000992	74.39	gold quality
right adrenal gland	UBERON:0001233	73.93	gold quality
hindlimb stylopod muscle	UBERON:0004252	73.87	gold quality
saliva-secreting gland	UBERON:0001044	73.79	gold quality
left adrenal gland	UBERON:0001234	73.20	gold quality
ectocervix	UBERON:0012249	73.08	gold quality
right adrenal gland cortex	UBERON:0035827	73.06	gold quality
left adrenal gland cortex	UBERON:0035825	72.78	gold quality
mucosa of paranasal sinus	UBERON:0005030	72.72	silver quality
apex of heart	UBERON:0002098	72.47	gold quality
adrenal cortex	UBERON:0001235	72.01	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	2.82

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

67 targeting NRG2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-4639-5P	99.81	67.37	1028
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-3617-5P	99.75	69.41	1968
HSA-MIR-641	99.75	69.35	1975
HSA-MIR-4446-5P	99.72	69.19	2544

Literature-anchored findings (GeneRIF, showing 12)

• examination of the effect of isoforms on angiogenesis (PMID:14722120)
• Nrg-2-induced Acetylcholine Receptor transcription requires an N-box motif and is regulated by alternative splicing. (PMID:15961242)
• Linkage interval for GLC1M was refined to a smaller region. The NRG2 gene was excluded as the causative gene for juvenile-onset primary open angle glaucoma. (PMID:17563728)
• Gln43 of NRG2beta is both necessary and sufficient for NRG2 stimulation of ErbB4 coupling to IL3 independence. (PMID:17945187)
• NRG2 was positive in almost all breast cancers studied. High expression is related to the biological aggressiveness of breast cancer. (PMID:17962208)
• reduced expression of NRG2 led to marginal increase in cell survival under arsenite-induced stress. (PMID:27345716)
• Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics. (PMID:33378376)
• Neuregulin 2 (NRG2) is expressed in gliomas and promotes migration of human glioma cells. (PMID:34284546)
• [Neuregulin 2 is highly expressed in glioma tissues to regulate glial fibrillary acidic protein expression via Akt signaling]. (PMID:34549707)
• NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis. (PMID:34996744)
• The relevance of EGFR, ErbB receptors and neuregulins in human adipocytes and adipose tissue in obesity. (PMID:36411648)
• Neuregulin 2 Is a Candidate Gene for Autism Spectrum Disorder. (PMID:38791584)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	nrg2a	ENSDARG00000077818
danio_rerio	nrg2b	ENSDARG00000086585
mus_musculus	Nrg2	ENSMUSG00000060275
rattus_norvegicus	Nrg2	ENSRNOG00000019093

Paralogs (3): NRG1 (ENSG00000157168), NRG4 (ENSG00000169752), NRG3 (ENSG00000185737)

Protein

Protein identifiers

Pro-neuregulin-2, membrane-bound isoform — O14511 (reviewed: O14511)

All UniProt accessions (2): O14511, F5GZS7

UniProt curated annotations — full annotation on UniProt →

Function. Direct ligand for ERBB3 and ERBB4 tyrosine kinase receptors. Concomitantly recruits ERBB1 and ERBB2 coreceptors, resulting in ligand-stimulated tyrosine phosphorylation and activation of the ERBB receptors. May also promote the heterodimerization with the EGF receptor.

Subunit / interactions. Interacts with ERBB3 and ERBB4.

Subcellular location. Cell membrane Secreted.

Tissue specificity. Restricted to the cerebellum in the adult.

Post-translational modifications. Proteolytic cleavage close to the plasma membrane on the external face leads to the release of the soluble growth factor form. Extensive glycosylation precedes the proteolytic cleavage.

Domain organisation. The cytoplasmic domain may be involved in the regulation of trafficking and proteolytic processing. Regulation of the proteolytic processing involves initial intracellular domain dimerization. ERBB receptor binding is elicited entirely by the EGF-like domain.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the neuregulin family.

Isoforms (8)

UniProt ID	Names	Canonical?
O14511-1	1	yes
O14511-2	2
O14511-3	3
O14511-4	4
O14511-5	5
O14511-6	6
O14511-7	DON-1B
O14511-8	DON-1R

RefSeq proteins (6): NP_001171864, NP_001397709, NP_004874, NP_053584, NP_053585, NP_053586 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000742	EGF	Domain
IPR002154	Neuregulin_C	Domain
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013098	Ig_I-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR040180	Neuregulin	Family
IPR057909	NRG2_N	Domain
IPR057911	NRG2_Ig-like	Domain

Pfam: PF02158, PF07679, PF25518

UniProt features (39 total): splice variant 9, compositionally biased region 7, region of interest 6, glycosylation site 5, disulfide bond 4, chain 2, topological domain 2, domain 2, propeptide 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O14511-F1	55.58	0.10

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (4): 257–311, 345–359, 353–370, 372–381

Glycosylation sites (5): 52, 53, 147, 278, 346

Function

Pathways and Gene Ontology

Reactome pathways

19 pathways

ID	Pathway
R-HSA-1227986	Signaling by ERBB2
R-HSA-1236394	Signaling by ERBB4
R-HSA-1250196	SHC1 events in ERBB2 signaling
R-HSA-1250342	PI3K events in ERBB4 signaling
R-HSA-1250347	SHC1 events in ERBB4 signaling
R-HSA-1251985	Nuclear signaling by ERBB4
R-HSA-1257604	PIP3 activates AKT signaling
R-HSA-1306955	GRB7 events in ERBB2 signaling
R-HSA-1358803	Downregulation of ERBB2:ERBB3 signaling
R-HSA-1963640	GRB2 events in ERBB2 signaling
R-HSA-1963642	PI3K events in ERBB2 signaling
R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-5673001	RAF/MAP kinase cascade
R-HSA-6785631	ERBB2 Regulates Cell Motility
R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-8847993	ERBB2 Activates PTK6 Signaling
R-HSA-8863795	Downregulation of ERBB2 signaling
R-HSA-9664565	Signaling by ERBB2 KD Mutants
R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants

MSigDB gene sets: 166 (showing top): RNGTGGGC_UNKNOWN, MODULE_52, MODULE_92, BENPORATH_ES_WITH_H3K27ME3, MODULE_45, GOMF_GROWTH_FACTOR_ACTIVITY, MODULE_16, GGGTGGRR_PAX4_03, CAGCTG_AP4_Q5, MODULE_66, MODULE_118, KEGG_ERBB_SIGNALING_PATHWAY, MODULE_379, GOBP_ERBB_SIGNALING_PATHWAY, PID_ERBB4_PATHWAY

GO Biological Process (5): signal transduction (GO:0007165), nervous system development (GO:0007399), intracellular signal transduction (GO:0035556), ERBB4 signaling pathway (GO:0038130), animal organ development (GO:0048513)

GO Molecular Function (2): signaling receptor binding (GO:0005102), growth factor activity (GO:0008083)

GO Cellular Component (4): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-10 pathways:

Category	Pathways
Signaling by ERBB2	7
Signaling by ERBB4	3
Signaling by Receptor Tyrosine Kinases	2
Signaling by ERBB2 in Cancer	2
Intracellular signaling by second messengers	1
Downregulation of ERBB2 signaling	1
PI3K/AKT Signaling in Cancer	1
MAPK1/MAPK3 signaling	1
Negative regulation of the PI3K/AKT network	1
Signaling by PTK6	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
system development	1
intracellular anatomical structure	1
signal transduction	1
ERBB signaling pathway	1
anatomical structure development	1
protein binding	1
receptor ligand activity	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1460 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NRG2	ERBB3	P21860	998
NRG2	ERBB4	Q15303	998
NRG2	NRG4	Q8WWG1	973
NRG2	EGFR	P00533	959
NRG2	ERBB2	P04626	930
NRG2	EGF	P01133	821
NRG2	AREG	P15514	742
NRG2	PVALB	P20472	665
NRG2	BTC	P35070	663
NRG2	EREG	O14944	630
NRG2	EPGN	Q6UW88	615
NRG2	HBEGF	Q99075	571
NRG2	NRG3	P56975	566
NRG2	WDR36	Q8NI36	553
NRG2	TGFA	P01135	506

IntAct

6 interactions, top by confidence:

A	B	Type	Score
BMP2K	NRG2	psi-mi:“MI:0915”(physical association)	0.490
NRG2	TSC22D2	psi-mi:“MI:0915”(physical association)	0.400
MPIG6B	NRG2	psi-mi:“MI:0915”(physical association)	0.400
LRRTM2	NRG2	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (7): NRG2 (Reconstituted Complex), NRG2 (Reconstituted Complex), NRG2 (Affinity Capture-RNA), NRG2 (Affinity Capture-RNA), TSC22D2 (Affinity Capture-MS), ERBB4 (Reconstituted Complex), ERBB3 (Reconstituted Complex)

ESM2 similar proteins: A0A1B0GUA5, A0A286YF58, A0A494C0N9, A0A494C0Y3, A0A7I2V3R4, A0JNN8, A2ARS0, A2VDX9, A5PJP1, A6NGB7, A8MVW0, C9JTQ0, O14511, O14559, O35392, O35569, O43541, O60548, O70220, P0DPE3, Q08102, Q14V87, Q19A40, Q29RK8, Q2HJ59, Q3TYP4, Q5BLP8, Q5T442, Q63244, Q6F5E0, Q6QNY0, Q6VUP9, Q80WY3, Q80XF7, Q8BQU6, Q8K025, Q8K071, Q8TD94, Q8WY41, Q8WZ71

Diamond homologs: A2AJ76, A2ASS6, D3YXG0, G4SLH0, O01761, O08775, O14511, O35136, O35181, O35569, O60469, O89026, O93383, P07522, P0DMY9, P0DMZ0, P12960, P13591, P14781, P22063, P28685, P35918, P43322, P56974, P56975, P57087, P86468, Q00968, Q02246, Q02297, Q05199, Q12860, Q5DTJ9, Q61330, Q62718, Q63198, Q6DR98, Q86TC9, Q8NDA2, Q8VHZ8

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
NRG2	up-regulates	ERBB4	binding
NRG2	up-regulates	ERBB3	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

134 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	114
Likely benign	9
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3436 predictions. Top by Δscore:

Variant	Effect	Δscore
5:139851600:TGA:T	donor_loss	1.0000
5:139851601:GAC:G	donor_loss	1.0000
5:139851602:A:AT	donor_loss	1.0000
5:139851603:CCT:C	donor_gain	1.0000
5:139851842:C:CT	acceptor_gain	1.0000
5:139852555:ATATA:A	acceptor_gain	1.0000
5:139852556:TATA:T	acceptor_gain	1.0000
5:139852557:ATA:A	acceptor_gain	1.0000
5:139852558:TA:T	acceptor_gain	1.0000
5:139852560:C:CC	acceptor_gain	1.0000
5:139852900:TCAC:T	donor_loss	1.0000
5:139852901:CACAT:C	donor_loss	1.0000
5:139852902:A:AC	donor_gain	1.0000
5:139852902:ACAT:A	donor_gain	1.0000
5:139852902:ACATC:A	donor_loss	1.0000
5:139852903:C:CT	donor_gain	1.0000
5:139852903:CA:C	donor_gain	1.0000
5:139852903:CAT:C	donor_gain	1.0000
5:139852903:CATC:C	donor_gain	1.0000
5:139852903:CATCT:C	donor_gain	1.0000
5:139853023:GTTTT:G	acceptor_gain	1.0000
5:139853024:TTTT:T	acceptor_gain	1.0000
5:139853025:TTT:T	acceptor_gain	1.0000
5:139853026:TT:T	acceptor_gain	1.0000
5:139853028:C:CC	acceptor_gain	1.0000
5:139853031:C:CT	acceptor_gain	1.0000
5:139853033:C:CT	acceptor_gain	1.0000
5:139853034:A:T	acceptor_gain	1.0000
5:139855672:TCA:T	donor_loss	1.0000
5:139855674:A:AC	donor_gain	1.0000

AlphaMissense

5493 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:139855701:A:G	C423R	1.000
5:139855709:C:T	G420D	1.000
5:139855710:C:G	G420R	1.000
5:139855718:A:G	L417P	1.000
5:139855721:A:G	L416P	1.000
5:139855724:G:T	A415D	1.000
5:139855730:C:T	C413Y	1.000
5:139855731:A:G	C413R	1.000
5:139855733:A:T	I412N	1.000
5:139855736:C:T	G411D	1.000
5:139855737:C:G	G411R	1.000
5:139855742:A:T	I409N	1.000
5:139855748:A:G	L407P	1.000
5:139865595:A:C	C381W	1.000
5:139865597:A:G	C381R	1.000
5:139865623:C:G	C372S	1.000
5:139865624:A:G	C372R	1.000
5:139865624:A:T	C372S	1.000
5:139871723:G:C	C370W	1.000
5:139871724:C:G	C370S	1.000
5:139871724:C:T	C370Y	1.000
5:139871725:A:G	C370R	1.000
5:139871725:A:T	C370S	1.000
5:139871756:G:C	C359W	1.000
5:139871757:C:G	C359S	1.000
5:139871757:C:T	C359Y	1.000
5:139871758:A:G	C359R	1.000
5:139871758:A:T	C359S	1.000
5:139871774:G:C	C353W	1.000
5:139871775:C:G	C353S	1.000

dbSNP variants (sampled 300 via entrez): RS1000013397 (5:139973057 T>C), RS1000016829 (5:139992881 C>A,G,T), RS1000022435 (5:139947282 A>G), RS1000025322 (5:140019077 A>G), RS1000059033 (5:139878941 G>A), RS1000062724 (5:140040036 T>C), RS1000065462 (5:139947001 T>G), RS1000086843 (5:139925976 A>G), RS1000090643 (5:139847570 A>G), RS1000123298 (5:139847283 C>A,G), RS1000147162 (5:139883410 C>T), RS1000173006 (5:139975506 G>A,C), RS1000182393 (5:140012093 G>C), RS1000186299 (5:139985940 G>A), RS1000204831 (5:139873952 C>T)

Disease associations

OMIM: gene MIM:603818 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual disability	Limited	Autosomal dominant

Mondo (2): autism spectrum disorder (MONDO:0005258), intellectual disability (MONDO:0001071)

Orphanet (1): NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004953_1	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia	4.000000e-06
GCST005951_151	Body mass index	6.000000e-07
GCST010396_31	Gut microbiota (bacterial taxa, hurdle binary method)	7.000000e-06
GCST90020028_1000	Hip circumference adjusted for BMI	8.000000e-09

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0008388	gamma wave measurement
EFO:0004340	body mass index
EFO:0007874	gut microbiome measurement
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, affects cotreatment, decreases expression	3
Vorinostat	affects cotreatment, increases expression	2
Acetaminophen	decreases expression	2
Benzo(a)pyrene	affects methylation, decreases methylation, increases methylation	2
Nickel	decreases expression	2
Tobacco Smoke Pollution	decreases expression	2
methylmercuric chloride	decreases expression	1
bisphenol A	affects methylation, affects cotreatment, increases methylation	1
terbufos	increases methylation	1
sodium arsenite	decreases expression	1
manganese chloride	increases expression	1
benzo(e)pyrene	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Arsenic	affects expression	1
Asbestos	affects methylation	1
Calcitriol	decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Fonofos	increases methylation	1
Estradiol	increases expression	1
Lipopolysaccharides	increases expression, decreases reaction	1
Manganese	increases expression	1
Melphalan	decreases expression	1
Parathion	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Silicon Dioxide	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1Z7	Abcam HeLa NRG2 KO	Cancer cell line	Female

Clinical trials (associated diseases)

496 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)